Xaciato is a U.S. prescription brand of clindamycin phosphate vaginal gel 2% indicated for bacterial vaginosis in female patients aged 12 years and older. It is distinct from vaginal cream and vaginal ovules. The product label describes a single-use applicator filled by the patient from an 8 g tube, with 5 g gel containing 100 mg of clindamycin delivered as a single dose.
The distinction matters because the similarly named Clindesse product is a 2% vaginal cream with a prefilled applicator and different barrier-contraception warnings. A clindamycin prescription or pharmacy listing must identify gel versus cream, not merely the ingredient and numerical percentage.
This page is a brand-specific reference for label identification, appropriate U.S. pharmacy access and risk counseling. It does not promise that Xaciato is currently stocked at any named pharmacy or suggest substituting one BV treatment for another without clinical assessment.
Xaciato contains clindamycin phosphate in a vaginal gel. Its label identifies bacterial vaginosis in female patients aged 12 years and older, a population detail that should not be generalized to every vaginal clindamycin brand.
For the broader diagnosis and treatment framework, see clindamycin for bacterial vaginosis. This brand page is not intended to diagnose symptoms or replace clinician assessment.
| Item | Xaciato identity | Do not confuse with |
|---|---|---|
| Form | 2% vaginal hydrogel | Vaginal cream or skin gel |
| Pack | 8 g tube | Clindesse prefilled cream applicator |
| Delivered unit | One user-filled applicator, 5 g / 100 mg | Entire tube as single delivered amount |
| Labeled population | Females age 12 years and older with BV | Other products’ indication wording |
| Barrier caution | Polyurethane condoms through day 7 post-treatment | Latex/rubber cream cautions |
| Access | U.S. prescription | OTC medicine or stock claim |
DailyMed describes an 8 g tube containing Xaciato 2% vaginal gel and a user-filled disposable applicator that delivers 5 g, equivalent to 100 mg clindamycin. The total tube amount and delivered gel amount are different, so a product comparison must not conflate the two.
This packaging is an important brand identifier. It is neither an oral liquid nor a tube of skin gel, and it is not identical to the prefilled Clindesse applicator.
Gel and cream have different vehicles. Even when both use clindamycin at 2%, their application devices, counseling and regulatory labeling can differ. A pharmacy search result displaying “2% clindamycin” may suppress those details.
The vaginal gel guide addresses the overall formulation; the cream guide covers the separate family. Product identity must be verified before dispensing.
Xaciato and Clindesse are both branded single-dose vaginal clindamycin medicines, but one is a gel loaded by the user and the other a prefilled cream. They are not automatic substitutes. The product instructions and age/indication language are also different.
See single-dose clindamycin cream versus gel for a decision-oriented comparison rather than combining the two on a single buy page.
The Xaciato label specifically warns that polyurethane condoms should not be used during treatment or for seven days following treatment because reliability may be reduced. It identifies latex or polyisoprene condoms as alternatives in this context.
Do not transfer the mineral-oil cream warning from Clindesse or Cleocin onto Xaciato. A pharmacist should discuss product-specific barrier contraception concerns with the patient based on the actual medicine dispensed.
The instructions for a user-filled applicator matter because the marketed tube contains more gel than the amount dispensed by that applicator. The patient should use the FDA-approved instructions supplied with Xaciato rather than measurements or technique copied from another product.
Ask the clinician or pharmacist about other vaginal products, sexual activity during treatment and any symptoms that warrant reassessment. This page avoids recreating a step-by-step treatment plan.
Xaciato is administered vaginally, but its labeling still includes warnings about C. difficile-associated diarrhea. Serious diarrhea, abdominal pain, fever or blood in stool warrants prompt evaluation after antibiotic exposure.
Review the C. difficile risk page. Patients with a history of clindamycin allergy or relevant gastrointestinal disease should discuss that history before treatment.
The Xaciato label identifies vulvovaginal candidiasis and vulvovaginal discomfort among reported reactions. Unexpected or persistent symptoms may reflect adverse effects, ongoing BV or another condition, so a clinician should decide whether reassessment is needed.
Because BV symptoms are not unique to one diagnosis, do not repeat an antibiotic on the assumption that the initial product failed or that another clindamycin form will be better.
Xaciato requires a valid U.S. prescription. A pharmacist should verify that the order identifies the gel brand or a permissible equivalent and confirm the user-filled applicator product. An online pharmacy should also provide licensing and pharmacist contact information.
The vaginal product purchase guide covers the legal fulfillment workflow without naming merchants or claiming stock.
DailyMed has a product label for Xaciato, including updated information, but a current label is not equivalent to live pharmacy inventory or payer approval. The brand’s supply should be checked with a dispensing pharmacy for the relevant location.
If a package is unavailable or insurance excludes it, the clinician and pharmacist can discuss alternatives. A substitution from gel to cream should not be assumed solely from 2% labeling.
Xaciato costs may vary by brand coverage, formulary requirements, the single-dose carton and actual pharmacy pricing. Comparing an 8 g tube listing with a 5 g delivered amount can also cause inaccurate cost-per-unit assumptions.
Our vaginal clindamycin cost guide provides evergreen variables rather than volatile or unsupported advertised prices.
Confirm Xaciato, clindamycin phosphate 2%, vaginal gel, 8 g tube and the included user-filled applicator. Review the route and product-specific instructions and ask about the seven-day polyurethane-condom caution.
The final match should be the pharmacist-approved product on the valid prescription. No listing or product photograph is enough to infer eligibility, safety or guaranteed availability.
Xaciato is a prescription 2% clindamycin phosphate vaginal gel used for bacterial vaginosis.
No. Xaciato is a user-filled gel product; Clindesse is a prefilled vaginal cream.
Its label describes an 8 g tube and a user-filled applicator delivering 5 g gel containing 100 mg clindamycin.
Female patients 12 years of age and older.
No. It is designed for vaginal use, not skin acne treatment.
Its label advises against polyurethane condoms during treatment and for seven days afterward.
No. It is a prescription drug in the United States.
No. The actual pharmacy must confirm supply.
Only when a clinician and pharmacist determine a suitable prescription change.